Indications
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Composition
- Active substance
- axitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Inlyta
- Active substance
- axitinib
- ATC code
- L01EK01
- Therapeutic area
- Carcinoma, Renal Cell
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Authorised
- EU authorisation
- 3 Sept 2012